Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran for Hereditary Angioedema
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
SAGA Metals Announces Closing of Fully Subscribed Non-Brokered Private Placement and Provides Corporate Update
Locksley Announces Major Advancement at Mojave as Structural Mapping Expands Scale of Antimony Target with a 400% Increase in Target Strike Length